查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1535590

外阴阴道念珠菌病 (VVC) 治疗市场 - 药物类别、疾病类型、给药途径、类型、配销通路、全球预测

Vulvovaginal Candidiasis (VVC) Treatment Market - Drug Class, Disease Type, Route of Administration, Type, Distribution Channel, Global Forecast 2024-2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 190 Pages | 商品交期: 2-3个工作天内

价格
简介目录

由于领先製药公司推出的产品激增，2024 年至 2032 年间，全球外阴阴道念珠菌病 (VVC) 治疗市场的复合年增长率将达到 4.5%。 VVC 是一种由念珠菌引起的常见真菌感染，影响全球数百万名女性，迫切需要有效的治疗方法。为此，医疗保健行业的主要参与者正在推出各种创新的抗真菌疗法和非处方治疗，包括外用乳膏、口服药物和阴道栓剂。

例如，2024年2月，新兴生物製药公司Mycovia Pharmaceuticals, Inc.宣布江苏恆瑞製药有限公司正式在中国上市VIVJOA(R)（奥替康唑）。这种创新的口服唑类抗霉菌药物现已可用于治疗严重的外阴阴道念珠菌病 (VVC)。

这些新产品的推出满足了人们对更有效、更方便、更适合患者的治疗方案日益增长的需求。公司正在投资研发以提高疗效、降低復发率并最大限度地减少副作用。新型配方和给药方法的引入体现了满足不同患者需求和改善治疗结果的承诺。随着市场随着这些进步而扩大，它有望为 VVC 提供更好的管理解决方案，推动整体市场成长并增强患者护理。

整个外阴阴道念珠菌病（VVC）治疗行业根据药物类别、疾病类型、给药途径、类型、配销通路和地区进行分类。

根据药物类别，克霉唑领域的外阴阴道念珠菌病(​​VVC) 治疗市场收入将在2024 年至2032 年实现值得称讚的复合年增长率。口服片剂，可有效缓解VVC 症状是管理这种常见真菌感染的基石。其长期的功效和安全性使其在医疗保健提供者和患者中持续受欢迎。克霉唑的持续供应及其成本效益进一步支持了其市场需求。由于 VVC 仍然普遍存在，克霉唑在治疗中的作用确保了其在 VVC 治疗领域的持续存在和重要性。

从疾病类型来看，复杂性VVC部分将在2024年至2032年出现显着增长。这导致人们更加关注开发和行销创新抗真菌疗法，包括更新的口服和局部疗法。对有效解决方案的需求是由降低復发率和改善患者治疗结果的需求所驱动的。随着医疗保健提供者寻求更有效的复杂 VVC 管理方案，随着先进治疗解决方案的引入，市场正在扩大。

欧洲外阴阴道念珠菌病(​​VVC) 治疗市场将于2024 年至2032 年呈现显着的复合年增长率。 VVC 是一种影响许多女性的常见真菌感染。该市场是由非处方药和处方药（包括外用和口服抗真菌药物）的需求所推动的。欧洲法规和医疗保健政策进一步支持创新疗法的可用性。因此，製药公司正在积极开发和推出新产品，以满足该地区对有效 VVC 治疗的需求。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 外阴阴道念珠菌病患病率增加
      • 非处方药的可用性
      • 越来越关注女性健康
    • 产业陷阱与挑战
      • 与抗真菌药物相关的不良反应
  • 成长潜力分析
  • 监管环境
    • 我们
    • 欧洲
    • 亚太地区
  • 管道分析
  • 报销版图
  • 未来市场趋势
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按药物类别，2021 - 2032 年

  • 主要趋势
  • 氟康唑
  • 克霉唑
  • 咪康唑
  • 制霉菌素
  • 酮康唑
  • 特比萘芬
  • 特康唑
  • 其他药物类别

第 6 章：市场估计与预测：按疾病类型，2021 - 2032

  • 主要趋势
  • 简单的 VVC
  • 复杂的VVC

第 7 章：市场估计与预测：按管理途径，2021 - 2032 年

  • 主要趋势
  • 口服
  • 专题
  • 静脉

第 8 章：市场估计与预测：按类型，2021 - 2032

  • 主要趋势
  • 处方药
  • 非处方药

第 9 章：市场估计与预测：按配销通路划分，2021 - 2032 年

  • 主要趋势
  • 医院药房
  • 零售药局
  • 网路药局

第 10 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
    • 欧洲其他地区
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
    • 亚太地区其他地区
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋
    • 中东和非洲其他地区

第 11 章：公司简介

  • Accord Healthcare Ltd.
  • Amneal Pharmaceuticals LLC
  • Astellas Pharma Inc.
  • Basilea Pharmaceutica Ltd.
  • Bayer AG
  • Bristol-Myers Squibb Company
  • Grupo Ferrer Internacional S.A.
  • Johnson & Johnson
  • Mycovia Pharmaceuticals, Inc.
  • Mylan N.V.
  • Pfizer, Inc.
  • Scynexis, Inc.
  • Teva Pharmaceutical Industries Ltd.
  • Zydus Cadila
简介目录
Product Code: 9746

Global Vulvovaginal Candidiasis (VVC) Treatment Market will witness 4.5% CAGR between 2024 and 2032 due to the surge in product launches from leading pharmaceutical companies. VVC, a common fungal infection caused by Candida species, affects millions of women globally, prompting a significant need for effective treatments. In response, major players in the healthcare sector are introducing a variety of innovative antifungal therapies and over-the-counter treatments, including topical creams, oral medications, and intravaginal suppositories.

For instance, in February 2024, Mycovia Pharmaceuticals, Inc., an emerging biopharmaceutical company, announced that Jiangsu Hengrui Pharmaceuticals Co., Ltd officially launched VIVJOA(R) (oteseconazole) in China. This innovative oral azole antifungal is now available for treating severe vulvovaginal candidiasis (VVC).

These new product launches address the growing demand for more effective, accessible, and patient-friendly treatment options. Companies are investing in research and development to enhance efficacy, reduce recurrence rates, and minimize side effects. The introduction of novel formulations and delivery methods reflects a commitment to meeting diverse patient needs and improving treatment outcomes. As the market expands with these advancements, it is poised to provide better management solutions for VVC, driving overall market growth and enhancing patient care.

The overall Vulvovaginal Candidiasis (VVC) Treatment Industry is classified based on the drug class, disease type, route of administration, type, distribution channel, and region.

Based on drug class, the vulvovaginal candidiasis (VVC) treatment market revenue from the clotrimazole segment will register a commendable CAGR from 2024 to 2032. Clotrimazole, available in various forms such as creams, suppositories, and oral tablets, offers effective relief from VVC symptoms and is a cornerstone in managing this common fungal infection. Its long-standing efficacy and safety profile contribute to its continued popularity among healthcare providers and patients. The consistent availability of clotrimazole and its cost-effectiveness further support its demand in the market. As VVC remains prevalent, clotrimazole's role in treatment ensures its sustained presence and significance in the VVC treatment landscape.

In terms of disease type, the complicated VVC segment will witness appreciable growth from 2024 to 2032. Complicated VVC, characterized by recurrent or severe infections, often requires more advanced treatment approaches compared to uncomplicated cases. This has led to an increased focus on developing and marketing innovative antifungal treatments, including newer oral and topical therapies. The demand for effective solutions is driven by the need for reduced recurrence rates and improved patient outcomes. As healthcare providers seek more effective management options for complicated VVC, the market is expanding with the introduction of advanced therapeutic solutions.

Europe vulvovaginal candidiasis (VVC) treatment market will exhibit a notable CAGR from 2024 to 2032. With a growing emphasis on women's health, European healthcare systems are prioritizing effective management options for VVC, which is a prevalent fungal infection affecting many women. The market is driven by the need for both over-the-counter and prescription treatments, including topical and oral antifungals. European regulations and healthcare policies further support the availability of innovative therapies. As a result, pharmaceutical companies are actively developing and launching new products to meet the demand for effective VVC treatments across the region.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing prevalence of vulvovaginal candidiasis
      • 3.2.1.2 Availability of over-the-counter medications
      • 3.2.1.3 Increasing focus on women's health
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 Adverse effects associated with antifungal medications
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
    • 3.4.1 U.S.
    • 3.4.2 Europe
    • 3.4.3 Asia Pacific
  • 3.5 Pipeline analysis
  • 3.6 Reimbursement landscape
  • 3.7 Future market trends
  • 3.8 Porter's analysis
  • 3.9 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company matrix analysis
  • 4.3 Competitive analysis of major market players
  • 4.4 Competitive positioning matrix
  • 4.5 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Fluconazole
  • 5.3 Clotrimazole
  • 5.4 Miconazole
  • 5.5 Nystatin
  • 5.6 Ketoconazole
  • 5.7 Terbinafine
  • 5.8 Terconazole
  • 5.9 Other drug classes

Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Uncomplicated VVC
  • 6.3 Complicated VVC

Chapter 7 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Oral
  • 7.3 Topical
  • 7.4 Intravenous

Chapter 8 Market Estimates and Forecast, By Type, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Prescription drugs
  • 8.3 OTC drugs

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 Hospital pharmacies
  • 9.3 Retail pharmacies
  • 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 10.1 Key trends
  • 10.2 North America
    • 10.2.1 U.S.
    • 10.2.2 Canada
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 France
    • 10.3.4 Spain
    • 10.3.5 Italy
    • 10.3.6 Netherlands
    • 10.3.7 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 China
    • 10.4.2 Japan
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 South Korea
    • 10.4.6 Rest of Asia Pacific
  • 10.5 Latin America
    • 10.5.1 Brazil
    • 10.5.2 Mexico
    • 10.5.3 Rest of Latin America
  • 10.6 Middle East and Africa
    • 10.6.1 South Africa
    • 10.6.2 Saudi Arabia
    • 10.6.3 UAE
    • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

  • 11.1 Accord Healthcare Ltd.
  • 11.2 Amneal Pharmaceuticals LLC
  • 11.3 Astellas Pharma Inc.
  • 11.4 Basilea Pharmaceutica Ltd.
  • 11.5 Bayer AG
  • 11.6 Bristol-Myers Squibb Company
  • 11.7 Grupo Ferrer Internacional S.A.
  • 11.8 Johnson & Johnson
  • 11.9 Mycovia Pharmaceuticals, Inc.
  • 11.10 Mylan N.V.
  • 11.11 Pfizer, Inc.
  • 11.12 Scynexis, Inc.
  • 11.13 Teva Pharmaceutical Industries Ltd.
  • 11.14 Zydus Cadila